
    
      The outcome measure used is the MADRS (Montgomery-Asberg Depression Rating Scale). This is
      administered at baseline and on a fortnightly basis. At study end response criteria is
      defined as a 50% reduction in total MADRS score and remission defined as a MADRS score of
      less than or equal to 10.

      Other outcome measures administered fortnightly are: BPRS (Brief Psychiatric Rating Scale),
      CORE (measure of melancholic symptoms), BDI (Beck Depression Inventory), CGI (Clinical Global
      Impression Scale), GAF (Global Assessment of Functioning Scale). A cognitive battery is also
      administered.

      Inclusion Criteria:

        -  Moderate to severe depressive symptoms as indicated as MADRS >20

        -  Failure to respond to a minimum of two antidepressant medications

        -  No increase or initiation of new antidepressant therapy in the four weeks prior to
           entering the trial Exclusion Criteria

        -  Have an unstable medical condition, neurological disorder or any history of seizure
           disorder or are currently pregnant or lactating

        -  Previous brain injury or surgery, any metal clips, plates or other metal items in the
           head, cardiac pacemaker

        -  In the opinion of the investigator, are a sufficient suicide risk to require immediate
           electroconvulsive therapy

        -  Have a current DSMIV diagnosis of substance abuse or dependence disorder, a diagnosis of
           a personality disorder or another axis 1 disorder
    
  